                         SEQUENCE LISTING

<110>  The Board of Trustees of the Leland Stanford Junior 
       University
 
<120>  METHODS OF TREATING INFECTIONS BY BLOCKING PATHOGEN MIMICS OF 
       CD47

<130>  STAN-1605PRV (S19-031)

<160>  4     

<170>  PatentIn version 3.5

<210>  1
<211>  119
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CV1

<400>  1

Glu Glu Glu Leu Gln Ile Ile Gln Pro Asp Lys Ser Val Leu Val Ala 
1               5                   10                  15      


Ala Gly Glu Thr Ala Thr Leu Arg Cys Thr Ile Thr Ser Leu Phe Pro 
            20                  25                  30          


Val Gly Pro Ile Gln Trp Phe Arg Gly Ala Gly Pro Gly Arg Val Leu 
        35                  40                  45              


Ile Tyr Asn Gln Arg Gln Gly Pro Phe Pro Arg Val Thr Thr Val Ser 
    50                  55                  60                  


Asp Thr Thr Lys Arg Asn Asn Met Asp Phe Ser Ile Arg Ile Gly Asn 
65                  70                  75                  80  


Ile Thr Pro Ala Asp Ala Gly Thr Tyr Tyr Cys Ile Lys Phe Arg Lys 
                85                  90                  95      


Gly Ser Pro Asp Asp Val Glu Phe Lys Ser Gly Ala Gly Thr Glu Leu 
            100                 105                 110         


Ser Val Arg Ala Lys Pro Ser 
        115                 


<210>  2
<211>  18
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  CD47 signal peptide

<400>  2

Met Trp Pro Leu Val Ala Ala Leu Leu Leu Gly Ser Ala Cys Cys Gly 
1               5                   10                  15      


Ser Ala 
        


<210>  3
<211>  142
<212>  PRT
<213>  Homo sapiens

<400>  3

Met Trp Pro Leu Val Ala Ala Leu Leu Leu Gly Ser Ala Cys Cys Gly 
1               5                   10                  15      


Ser Ala Gln Leu Leu Phe Asn Lys Thr Lys Ser Val Glu Phe Thr Phe 
            20                  25                  30          


Cys Asn Asp Thr Val Val Ile Pro Cys Phe Val Thr Asn Met Glu Ala 
        35                  40                  45              


Gln Asn Thr Thr Glu Val Tyr Val Lys Trp Lys Phe Lys Gly Arg Asp 
    50                  55                  60                  


Ile Tyr Thr Phe Asp Gly Ala Leu Asn Lys Ser Thr Val Pro Thr Asp 
65                  70                  75                  80  


Phe Ser Ser Ala Lys Ile Glu Val Ser Gln Leu Leu Lys Gly Asp Ala 
                85                  90                  95      


Ser Leu Lys Met Asp Lys Ser Asp Ala Val Ser His Thr Gly Asn Tyr 
            100                 105                 110         


Thr Cys Glu Val Thr Glu Leu Thr Arg Glu Gly Glu Thr Ile Ile Glu 
        115                 120                 125             


Leu Lys Tyr Arg Val Val Ser Trp Phe Ser Pro Asn Glu Asn 
    130                 135                 140         


<210>  4
<211>  124
<212>  PRT
<213>  Homo sapiens

<400>  4

Gln Leu Leu Phe Asn Lys Thr Lys Ser Val Glu Phe Thr Phe Cys Asn 
1               5                   10                  15      


Asp Thr Val Val Ile Pro Cys Phe Val Thr Asn Met Glu Ala Gln Asn 
            20                  25                  30          


Thr Thr Glu Val Tyr Val Lys Trp Lys Phe Lys Gly Arg Asp Ile Tyr 
        35                  40                  45              


Thr Phe Asp Gly Ala Leu Asn Lys Ser Thr Val Pro Thr Asp Phe Ser 
    50                  55                  60                  


Ser Ala Lys Ile Glu Val Ser Gln Leu Leu Lys Gly Asp Ala Ser Leu 
65                  70                  75                  80  


Lys Met Asp Lys Ser Asp Ala Val Ser His Thr Gly Asn Tyr Thr Cys 
                85                  90                  95      


Glu Val Thr Glu Leu Thr Arg Glu Gly Glu Thr Ile Ile Glu Leu Lys 
            100                 105                 110         


Tyr Arg Val Val Ser Trp Phe Ser Pro Asn Glu Asn 
        115                 120                 


